You are here

Positive Results Reported for Breast Cancer Vaccine

Treatment targets cancer-associated antigen mammaglobin-A

A DNA vaccine targeting mammaglobin-A, a breast cancer-associated antigen, was shown to be safe and effective in eliciting immune responses in women with metastatic breast cancer, according to a study published in Clinical Cancer Research.

“This study builds on extensive studies of mammaglobin-A immunobiology and confirms that it is an attractive target for immune intervention in breast cancer patients,” said author William E. Gillanders, MD.

“Mammaglobin-A is an excellent target for breast cancer vaccine therapy because it is specific to breast cancer tissue, and it is over-expressed in most breast cancers, including noninvasive, invasive, or metastatic breast cancers,” Gillanders said. “These unique properties mean that a mammaglobin-A vaccine could be therapeutic, given after breast cancer has developed to treat or prevent disease recurrence, or preventive, given to patients before they are diagnosed with breast cancer.”

Gillanders and his colleagues treated 14 patients with metastatic breast cancer with the mammaglobin-A vaccine. The patients reported only minor adverse effects, such as injection-site reactions or temporary fevers.

Using flow cytometry, the researchers found that the frequency of mammaglobin-A–specific CD8 T cells at baseline increased more than fourfold and after vaccination, indicating a robust immune response.

“Measuring mammaglobin-A–specific CD8 T cells is one way to measure vaccine efficacy,” Gillanders explained. “Although CD8 T cells are only one component of the immune response, they are arguably the most important component.”

The analysis also showed that the patients treated with the vaccine had prolonged progression-free survival compared with those who did not receive the vaccine; however, the study was not designed to compare survival among these groups.

“I predict that this vaccine and similar vaccines could have the greatest clinical impact in patients who have completed standard treatment regimens, such as chemotherapy, surgery, or radiation, to minimize the risk of recurrence,” Gillanders said. “That would help to improve the overall success rate associated with current treatment paradigms.”

Sources: AACR; December 1, 2014; and Clinical Cancer Research; December 1, 2014.

Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
Study lists steps that could save close to $300 billion a year
While many victims used THC, the cause remains elusive
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market
Data show PTC Therapeutics drug preserves lung function